subscribeSubscribe
Genentech`s Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.

Genentech`s Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.
FDA
02 Feb 2022
Share Share
PhaseBio Names Jonathan Birchall as Chief Commercial Officer

PhaseBio Names Jonathan Birchall as Chief Commercial Officer
BUSINESSWIRE
18 Nov 2021
Share Share
Seagen undaunted by AstraZeneca-Daiichi`s Enhertu

Seagen undaunted by AstraZeneca-Daiichi`s Enhertu
K. Dunleavy FIERCEPHARMA
30 Oct 2021
Share Share
Canada`s Xenon touts win for its daily epilepsy pill

Canada`s Xenon touts win for its daily epilepsy pill
P. Schloesser ENDPTS
05 Oct 2021
Share Share
AstraZeneca`s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan

AstraZeneca`s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan
P. Schloesser ENDPTS
05 Oct 2021
Share Share
AZ-Daiichi, Biogen-Samsung, Clover and more—Fierce Pharma Asia

AZ-Daiichi, Biogen-Samsung, Clover and more—Fierce Pharma Asia
Angus Liu FIERCEPHARMA
24 Sep 2021
Share Share
Enhertu delivers massive progression edge over Kadcyla

Enhertu delivers massive progression edge over Kadcyla
Angus Liu FIERCEPHARMA
20 Sep 2021
Share Share
Genentech`s Biological Ado-Trastuzumab Emtansine Receives Approval In US

Genentech`s Biological Ado-Trastuzumab Emtansine Receives Approval In US
FDA
27 Sep 2020
Share Share
Chugai Obtains Approval for Additional Indication of Kadcyla

Chugai Obtains Approval for Additional Indication of Kadcyla
CHUGAI-PHARM.CO
21 Aug 2020
Share Share
Chuagi gets Japanese additional indication approval for Kadcyla

Chuagi gets Japanese additional indication approval for Kadcyla
PHARMABIZZ
21 Aug 2020
Share Share